EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma.

@article{Brandes2010EORTCS2,
  title={EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma.},
  author={Alba A Brandes and Roger Stupp and Peter Hau and Denis Lacombe and Thierry Gorlia and Alicia Tosoni and Ren{\'e} Olivier Mirimanoff and Johan M. Kros and Martin J. van den Bent},
  journal={European journal of cancer},
  year={2010},
  volume={46 2},
  pages={348-54}
}
BACKGROUND Glioblastoma is a highly vascularised tumour with a high expression of both vascular endothelial growth factor (VEGF) and VEGFR. PTK787/ZK222584 (PTK/ZK, vatalanib), a multiple VEGF receptor inhibitor, blocks the intracellular tyrosine kinase activity of all known VEGF receptors and is therefore suitable for long-term therapy of pathologic tumour neovascularisation. PATIENTS AND METHODS The study was designed as an open-label, phase I/II study. A classic 3+3 design was selected… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

Advances in Biology and Treatment of Glioblastoma

Somasundaram
Current Cancer Research • 2017

Antiangiogenic therapy for glioblastoma: current status and future prospects.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2014

References

Publications referenced by this paper.
Showing 1-10 of 10 references

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2007

Response criteria for phase II studies of supratentorial malignant glioma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 1990

Similar Papers

Loading similar papers…